Dr. Michael Brent Bernstein, MD

Dr. Bernstein practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Bernstein's NPI, 1922234251, was assigned on June 1, 2009. Dr. Bernstein graduated from Albert Einstein College of Medicine in 2009. Dr. Bernstein holds New York license 279111.

Dr. Bernstein's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Bernstein's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Bernstein to 4 more group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bernstein practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bernstein's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bernstein is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Bernstein's licenses on file in 2 states: New York and Florida.

Dmand AI lists bone cancer radiation, breast cancer radiation, prostate cancer radiation and uterine cancer radiation among the conditions Dr. Bernstein treats.

CMS data shows 2,104 Medicare services from Dr. Bernstein across 15 procedure codes in 2024, for 432 Medicare patients. Medicare paid $171,599 for them.

CMS counts 432 Medicare patients who saw Dr. Bernstein in 2024. The largest group is 65 to 74, with 207 patients. 75% of them have cancer, and 75% have high blood pressure. 11% are also on Medicaid. Their average risk score is 1.98, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bernstein's median patient age at 70, with 51% women.

In 2024, Dr. Bernstein wrote 222 Medicare Part D claims for 109 patients. 91% of them were for generic drugs. CMS names the drug for 156 of them, across 4 drugs with 11 or more claims each, at $29,966 in total drug cost. In 2023, CMS named 104 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Bernstein for performance year 2024, reported as part of a group. Dr. Bernstein accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bernstein as offering telehealth.

Dmand AI links 16 papers to Dr. Bernstein, published from 2007 to 2024. 2014 was the busiest year, with 4. The most frequent topics are Breast Neoplasms, Immunotherapy and Mice, Inbred C57BL. Dr. Bernstein has published most often in Int J Radiat Oncol Biol Phys. Dr. Bernstein's most frequent co-authors are Shalom Kalnicki, MD, Lior Z. Braunstein, MD and John J. Cuaron, MD.

CMS Open Payments shows 6 general payments to Dr. Bernstein from 3 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 100% of the total. Novocure Inc. paid the most, $169.

Dr. Bernstein graduated from Albert Einstein College of Medicine in 2009.

Dr. Bernstein is in network with 11 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.